Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

NCT03834519 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

793

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Olaparib
DRUG: Abiraterone acetate
DRUG: Prednisone
DRUG: Enzalutamide
DRUG: Prednisolone

Sponsor

Merck Sharp & Dohme LLC